196 Chapter 9 Table 1. Patient and clinical characteristics stratified by sex All patients N= 3384 Female patients N= 1431 Male patients N= 1953 p-value a Demographics Female sex, n (%) 1431 (42.3) 1431 (100) 0 (0) Age in years, median (IQR) 60 (47-70) 60 (47-71) 60 (48-70) 0.164 Race, n (%) <0.001 White 2063 (61.0) 806 (56.3) 1257 (64.4) Black 1201 (35.5) 581 (40.6) 620 (31.7) Other 120 (3.5) 44 (3.1) 76 (3.9) Comorbidities, n (%) Diabetes mellitus 1296 (38.5) 562 (39.5) 734 (37.8) 0.316 Hemodialysis dependent 643 (19.1) 309 (21.7) 334 (17.2) 0.001 Organ transplant 218 (6.5) 78 (5.5) 140 (7.2) 0.047 Injection drug use 206 (6.1) 64 (4.5) 142 (7.3) 0.001 Corticosteroid use past 30 days 670 (20.0) 315 (22.2) 355 (18.4) 0.008 Foreign body present 1831 (54.3) 817 (57.5) 1014 (52.0) 0.002 Initial source of bacteremia, n (%) 0.037 Endovascular 912 (27.0) 421 (29.4) 491 (25.1) Pulmonary 319 (9.4) 136 (9.5) 183 (9.4) Skin/soft tissue 707 (20.9) 301 (21.0) 406 (20.8) Other 770 (22.8) 311 (21.7) 459 (23.5) Unknown 676 (20.0) 262 (18.3) 414 (21.2) Micro-organism, n (%) Methicillin-resistance (MRSA) 1537 (46.1) 697 (49.4) 840 (43.6) 0.001 USA300b 303 (9.7) 130 (9.8) 173 (9.6) 0.854 Presentation, median (IQR) Days of symptoms until diagnosis c 2 (1-5) 2 (1-4) 2 (1-5) 0.014 APS score 8 (5-13) 9 (5-13) 8 (5-13) 0.037
RkJQdWJsaXNoZXIy MTk4NDMw